PMID- 25968464
OWN - NLM
STAT- MEDLINE
DCOM- 20160226
LR  - 20220409
IS  - 1878-5905 (Electronic)
IS  - 0142-9612 (Print)
IS  - 0142-9612 (Linking)
VI  - 59
DP  - 2015 Aug
TI  - Inhibition of MAP kinase/NF-kB mediated signaling and attenuation of 
      lipopolysaccharide induced severe sepsis by cerium oxide nanoparticles.
PG  - 160-71
LID - S0142-9612(15)00372-5 [pii]
LID - 10.1016/j.biomaterials.2015.04.025 [doi]
AB  - Sepsis is a life threatening disease that is associated with high mortality. 
      Existing treatments have failed to improve survivability in septic patients. The 
      purpose of this present study is to evaluate whether cerium oxide nanoparticles 
      (CeO2NPs) can prevent lipopolysaccharide (LPS) induced severe sepsis mortality by 
      preventing hepatic dysfunction in male Sprague Dawley rats. Administration of a 
      single dose (0.5 mg/kg) of CeO2NPs intravenously to septic rats significantly 
      improved survival rates and functioned to restore body temperature, respiratory 
      rate and blood pressure towards baseline. Treatment-induced increases in animal 
      survivability were associated with decreased hepatic damage along with reductions 
      in serum cytokines/chemokines, and diminished inflammatory related signaling. 
      Kupffer cells and macrophage cells exposed to CeO2NPs exhibited decreases in 
      LPS-induced cytokine release (TNF-alpha, IL-1beta, IL-6, HMGB1) which were associated 
      with diminished cellular ROS, reduced levels of nitric oxide synthase (iNOS), 
      cyclooxygenase 2 (COX-2), and decreased nuclear factor-kappa light chain enhancer 
      of activated B cells (NF-kB) transcriptional activity. The findings of this study 
      indicate that CeO2NPs may be useful as a therapeutic agent for sepsis.
CI  - Copyright (c) 2015 Elsevier Ltd. All rights reserved.
FAU - Selvaraj, Vellaisamy
AU  - Selvaraj V
AD  - Center for Diagnostic Nanosystems, Marshall University, Huntington, WV, USA.
FAU - Nepal, Niraj
AU  - Nepal N
AD  - Center for Diagnostic Nanosystems, Marshall University, Huntington, WV, USA.
FAU - Rogers, Steven
AU  - Rogers S
AD  - Center for Diagnostic Nanosystems, Marshall University, Huntington, WV, USA.
FAU - Manne, Nandini D P K
AU  - Manne ND
AD  - Center for Diagnostic Nanosystems, Marshall University, Huntington, WV, USA.
FAU - Arvapalli, Ravikumar
AU  - Arvapalli R
AD  - Center for Diagnostic Nanosystems, Marshall University, Huntington, WV, USA.
FAU - Rice, Kevin M
AU  - Rice KM
AD  - Center for Diagnostic Nanosystems, Marshall University, Huntington, WV, USA.
FAU - Asano, Shinichi
AU  - Asano S
AD  - Center for Diagnostic Nanosystems, Marshall University, Huntington, WV, USA.
FAU - Fankhanel, Erin
AU  - Fankhanel E
AD  - Center for Diagnostic Nanosystems, Marshall University, Huntington, WV, USA.
FAU - Ma, Jane J
AU  - Ma JJ
AD  - Health Effects Laboratory Division, NIOSH, Morgantown, WV, USA.
FAU - Shokuhfar, Tolou
AU  - Shokuhfar T
AD  - Department of Mechanical Engineering and Engineering Mechanics, Michigan 
      Technological University, Houghton, MI, USA.
FAU - Maheshwari, Mani
AU  - Maheshwari M
AD  - Center for Diagnostic Nanosystems, Marshall University, Huntington, WV, USA.
FAU - Blough, Eric R
AU  - Blough ER
AD  - Center for Diagnostic Nanosystems, Marshall University, Huntington, WV, USA; 
      Department of Pharmacology, Physiology and Toxicology, Joan C. Edwards School of 
      Medicine, Marshall University, Huntington, WV, USA; Department of Cardiology, 
      Joan C. Edwards School of Medicine, Marshall University, Huntington, WV, USA; 
      Department of Pharmaceutical Sciences and Research, School of Pharmacy, Marshall 
      University, Huntington, WV, USA. Electronic address: blough@marshall.edu.
LA  - eng
GR  - CC999999/Intramural CDC HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150515
PL  - Netherlands
TA  - Biomaterials
JT  - Biomaterials
JID - 8100316
RN  - 0 (Lipopolysaccharides)
RN  - 0 (NF-kappa B)
RN  - 30K4522N6T (Cerium)
RN  - 619G5K328Y (ceric oxide)
RN  - EC 2.7.11.24 (Mitogen-Activated Protein Kinases)
SB  - IM
MH  - Animals
MH  - Cerium/*therapeutic use
MH  - Lipopolysaccharides/*toxicity
MH  - Metal Nanoparticles/chemistry/*therapeutic use
MH  - Microscopy, Electron, Scanning
MH  - Microscopy, Electron, Transmission
MH  - Mitogen-Activated Protein Kinases/*metabolism
MH  - NF-kappa B/*antagonists & inhibitors
MH  - Rats
MH  - Sepsis/chemically induced/*drug therapy
MH  - *Signal Transduction
PMC - PMC4565726
MID - NIHMS719487
OID - NLM: HHSPA719487
OTO - NOTNLM
OT  - Cerium oxide nanoparticles
OT  - Cytokines
OT  - Lipopolysaccharide
OT  - Macrophage
OT  - Sepsis
COIS- Conflict of interest: The authors declare no conflict of interest.
EDAT- 2015/05/15 06:00
MHDA- 2016/02/27 06:00
PMCR- 2015/09/10
CRDT- 2015/05/14 06:00
PHST- 2015/01/05 00:00 [received]
PHST- 2015/04/03 00:00 [revised]
PHST- 2015/04/08 00:00 [accepted]
PHST- 2015/05/14 06:00 [entrez]
PHST- 2015/05/15 06:00 [pubmed]
PHST- 2016/02/27 06:00 [medline]
PHST- 2015/09/10 00:00 [pmc-release]
AID - S0142-9612(15)00372-5 [pii]
AID - 10.1016/j.biomaterials.2015.04.025 [doi]
PST - ppublish
SO  - Biomaterials. 2015 Aug;59:160-71. doi: 10.1016/j.biomaterials.2015.04.025. Epub 
      2015 May 15.